<?xml version="1.0" encoding="UTF-8"?>
<p>The number and proportion of patients who experienced treatment-emergent adverse events (AEs) and treatment-related adverse events (TRAEs) was listed and summarized by treatment group. The full analysis set (FAS) population (efficacy analyses) was defined as all patients who were randomized and received protocol-required cisplatin and study treatment. The safety analysis population consisted of all patients who received study treatment.</p>
